| Similar Articles |
|---|
 |
The Motley Fool
January 25, 2007
Brian Gorman |
Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.   |
The Motley Fool
April 25, 2005
Brian Gorman |
Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar. |
The Motley Fool
January 27, 2006
Brian Gorman |
Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet. |
The Motley Fool
April 28, 2006
Brian Gorman |
Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
October 30, 2006
Brian Gorman |
Quality in Covance Some investors are pulling back from the company's stock, but Covance will continue to deliver. |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
January 27, 2005
Brian Gorman |
Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results. |
The Motley Fool
June 15, 2006
Brian Gorman |
Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note. |
The Motley Fool
July 22, 2009
Robert Steyer |
Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry. |
The Motley Fool
July 22, 2011 |
Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
The Motley Fool
April 24, 2009
Robert Steyer |
Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
June 7, 2005
Brian Gorman |
Covance Under Fire The contract research company could suffer at the hands of the animal-rights group PETA. The value of a company's public image is hard to quantify. For investors, this is definitely a case worth watching. |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play? |
The Motley Fool
October 1, 2008
Brian Orelli |
WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap. |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
The Motley Fool
October 3, 2011
Brian D. Pacampara |
Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion. |
Pharmaceutical Executive
December 1, 2012
Torrey et al. |
Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
The Motley Fool
July 27, 2011
Michael Olsen |
Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment. |
The Motley Fool
November 30, 2007
Brian Orelli |
Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way. |
The Motley Fool
January 3, 2006
W.D. Crotty |
A Value Test for SFBC Its stock soars after the two most senior executives leave the drug development company. So, is this a value play? |
The Motley Fool
August 9, 2006
Brian Gorman |
Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note. |
The Motley Fool
July 29, 2005
Stephen Ellis |
eResearch Misses a Beat Is eResearch Technology a dirt-cheap company or value trap? There are good reasons to suggest that the provider of ECG collection and interpretation services to the pharmaceutical industry does not deserve the shellacking that it has been receiving over the past year. |
